Pacer Advisors Inc. Increases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 15.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,099,378 shares of the specialty pharmaceutical company's stock after purchasing an additional 278,465 shares during the quarter. Pacer Advisors Inc. owned 3.40% of Jazz Pharmaceuticals worth $233,892,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. Capital World Investors purchased a new position in Jazz Pharmaceuticals during the first quarter worth about $171,943,000. Swedbank AB purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter worth about $106,936,000. Rubric Capital Management LP acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth approximately $65,812,000. Baupost Group LLC MA raised its stake in shares of Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock valued at $136,000,000 after purchasing an additional 440,552 shares during the period. Finally, Millennium Management LLC grew its holdings in Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company's stock valued at $48,122,000 after purchasing an additional 427,246 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on JAZZ shares. Cantor Fitzgerald reissued an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Piper Sandler reiterated an "overweight" rating and set a $163.00 price objective (down from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday. Royal Bank of Canada increased their price target on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. HC Wainwright reaffirmed a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a research report on Monday, August 19th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $175.33.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 3,700 shares of the firm's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock valued at $720,160 over the last ninety days. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $5.86 during trading on Thursday, hitting $125.10. 757,373 shares of the company's stock were exchanged, compared to its average volume of 678,467. The company has a market cap of $7.56 billion, a PE ratio of 17.34, a P/E/G ratio of 0.98 and a beta of 0.57. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock's 50 day moving average price is $112.92 and its two-hundred day moving average price is $110.52.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.